Physician
Isaac Spine Joint & Pain Institute
Isaac Spine Joint & Pain Institute was paid $2.76M by Medicaid between Jan 2018 and Dec 2024, across 41 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 50% of everything it billed.
33Billing provider infoISAAC SPINE JOINT & PAIN INSTITUTE
NASHVILLE, TN 37211
NASHVILLE, TN 37211
33aNPI1538400668assigned 03/14/2013
33bProvider typePain Medicine (Physical Medicine & Rehabilitation) Physician
28Total paid$2.76M
24GClaims138,719
24DCodes billed41
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pain Medicine (Physical Medicine & Rehabilitation) Physician providers in Tennessee
Rank by total paid#2 of 9
Median peer was paid$213K
This provider vs. median13×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 22,855 | $649K | |
| 2019 | 25,235 | $567K | |
| 2020 | 22,287 | $445K | |
| 2021 | 22,523 | $358K | |
| 2022 | 17,809 | $295K | |
| 2023 | 15,728 | $246K | |
| 2024incomplete | 12,282 | $199K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 50% | 67,675 | 57,598 | $1.39M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 6.3% | 13,632 | 11,839 | $174K |
| 64483 | 5.9% | 1,583 | 1,187 | $162K | |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4.9% | 3,980 | 3,448 | $134K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 4.3% | 5,157 | 4,612 | $120K |
| 64635 | 4.3% | 1,045 | 555 | $119K | |
| 64493 | 3.3% | 1,458 | 822 | $92K | |
| 95886 | 2.6% | 1,015 | 860 | $73K | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 2.2% | 2,971 | 2,296 | $60K |
| 80305 | 2.2% | 11,261 | 9,604 | $60K | |
| 64636 | 2.0% | 1,225 | 484 | $55K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.8% | 3,415 | 2,721 | $51K |
29 more codes
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.4% | 2,024 | $37K |
| 99204 | Doctor's office visit, new patient (more involved) | 1.3% | 545 | $36K |
| 64494 | 1.2% | 1,394 | $34K | |
| 99408 | 1.2% | 4,940 | $32K | |
| 95911 | 1.1% | 311 | $31K | |
| L0650 | Lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panel(s), produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf | <1% | 50 | $22K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 430 | $18K |
| 62323 | <1% | 171 | $18K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,385 | $10K |
| 96102 | <1% | 609 | $8K | |
| 95910 | <1% | 62 | $5K | |
| 96127 | <1% | 2,426 | $4K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 63 | $3K |
| 64495 | <1% | 127 | $3K | |
| 64640 | <1% | 16 | $2K | |
| 64479 | <1% | 12 | $2K | |
| 96146 | <1% | 3,341 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,373 | $1K |
| G0396 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes | <1% | 96 | $1K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,883 | $1K |
| 20610 | <1% | 35 | $1K | |
| 99406 | <1% | 166 | $638.85 | |
| 20611 | <1% | 16 | $549.24 | |
| 81025 | <1% | 51 | $180.76 | |
| G8428 | Current list of medications not documented as obtained, updated, or reviewed by the eligible clinician, reason not given | 0% | 60 | $0.00 |
| G8950 | Elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented | 0% | 19 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 583 | $0.00 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 42 | $0.00 |
| G8730 | Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | 0% | 72 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialISAAC, VICTOR (MD, MEDICAL DIRECTOR)